Yulia Surovtseva
Director 3Cards
Additional Titles
Postdoctoral Fellow
Postdoctoral Fellow
Contact Info
About
Titles
Director 3
Postdoctoral Fellow; Postdoctoral Fellow
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yulia Surovtseva's published research.
Publications Timeline
A big-picture view of Yulia Surovtseva's research output by year.
Sheila Umlauf
Michael Girardi, MD, FAAD
Susan Baserga, MD, PhD
Francine Foss, MD
Laura Abriola
Sa Rang Kim, MD
22Publications
694Citations
Publications
2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 1-15. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchConceptsMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitroThe cytidine deaminase APOBEC3A regulates nucleolar function to promote cell growth and ribosome biogenesis
McCool M, Bryant C, Abriola L, Surovtseva Y, Baserga S. The cytidine deaminase APOBEC3A regulates nucleolar function to promote cell growth and ribosome biogenesis. PLOS Biology 2024, 22: e3002718. PMID: 38976757, PMCID: PMC11257408, DOI: 10.1371/journal.pbio.3002718.Peer-Reviewed Original ResearchAltmetricConceptsRibosome biogenesis factorsRibosome biogenesisBiogenesis factorsCell growthNucleolar functionRegulation of nucleolar functionHuman ribosome biogenesisProtein synthesisProduction of ribosomesFamily of proteinsSource of mutagenesisLevel of protein synthesisCytidine deaminase familyIncreased cell growthPromote cell growthPre-rRNAPotential direct rolePre-mRNATransient overexpressionRibosomeGenomic mutationsBiogenesisMCF10A cellsMaturation stepsAPOBEC3ADiscovery of novel microRNA mimic repressors of ribosome biogenesis
Bryant C, McCool M, González G, Abriola L, Surovtseva Y, Baserga S. Discovery of novel microRNA mimic repressors of ribosome biogenesis. Nucleic Acids Research 2024, 52: 1988-2011. PMID: 38197221, PMCID: PMC10899765, DOI: 10.1093/nar/gkad1235.Peer-Reviewed Original ResearchAltmetric
2021
Probing Microbiome Genotoxicity: A Stable Colibactin Provides Insight into Structure–Activity Relationships and Facilitates Mechanism of Action Studies
Wernke KM, Tirla A, Xue M, Surovtseva YV, Menges FS, Herzon SB. Probing Microbiome Genotoxicity: A Stable Colibactin Provides Insight into Structure–Activity Relationships and Facilitates Mechanism of Action Studies. Journal Of The American Chemical Society 2021, 143: 15824-15833. PMID: 34524796, DOI: 10.1021/jacs.1c07559.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFanconi anemia DNA repair pathwayBiosynthetic gene clusterDNA repair pathwaysGene clusterRepair pathwaysDNA bindingBacterial phenotypesInduces DNAGenotoxic effectsHuman microbiomeColibactinBiosynthetic precursorNatural product structuresBiological studiesPathwayStructure-activity relationshipsAction studiesGenotoxic metabolitesOrganismsOncogenesisDNATumorigenesisMicrobiomeFacilitate mechanismsPhenotype
2020
854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy
Yumeen S, Mirza F, Lewis J, King A, Kim S, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy. Journal Of Investigative Dermatology 2020, 140: s111. DOI: 10.1016/j.jid.2020.03.870.Peer-Reviewed Original ResearchScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchCitationsAltmetricJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition
2019
676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma
Yumeen S, King A, Kim S, Lewis J, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma. Journal Of Investigative Dermatology 2019, 139: s116. DOI: 10.1016/j.jid.2019.03.752.Peer-Reviewed Original Research
2018
Model Colibactins Exhibit Human Cell Genotoxicity in the Absence of Host Bacteria
Shine EE, Xue M, Patel JR, Healy AR, Surovtseva YV, Herzon SB, Crawford JM. Model Colibactins Exhibit Human Cell Genotoxicity in the Absence of Host Bacteria. ACS Chemical Biology 2018, 13: 3286-3293. PMID: 30403848, PMCID: PMC7001666, DOI: 10.1021/acschembio.8b00714.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHost bacteriaGenotoxic secondary metabolitesDNA double-strand breaksDNA interstrandSpecific protein domainsWild-type pathwayDouble-strand breaksFull molecular mechanismsCell culturesFamily of metabolitesHuman cell linesProtein domainsPresence of membranesModule skippingCellular phenotypesExtracellular supplementationNative pathwaysHuman cell culturesMolecular mechanismsSecondary metabolitesHuman cellsColibactinEfficient DNA interstrandObserved modulesPhenotypeHigh throughput discovery of novel regulators of human ribosome biogenesis
Baserga S, Farley‐Barnes K, McCann K, Ogawa L, Merkel J, Surovtseva Y. High throughput discovery of novel regulators of human ribosome biogenesis. The FASEB Journal 2018, 32: 526.25-526.25. DOI: 10.1096/fasebj.2018.32.1_supplement.526.25.Peer-Reviewed Original ResearchConceptsRibosome biogenesisNucleolar functionNumber of nucleoliMammalian cellsGenome-wide siRNA screenRNA polymerase I transcriptionHuman ribosome biogenesisPre-ribosomal RNAPolymerase I transcriptionExperimental Biology 2018 MeetingHigh-throughput discoveryNucleolar proteinsRibosomal DNAProtein regulatorsI transcriptionNew regulatorNovel regulatorSiRNA screenBiogenesisHuman cellsProteinRegulatorNucleoliFASEB JournalThroughput discovery
News
News
- November 14, 2023
Nine YSM Staff Recognized With Linda K. Lorimer Award for Distinguished Service
- March 15, 2022
New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
- April 29, 2020Source: YaleNews
Battling COVID-19 with robots and a library of chemicals
- March 14, 2016
Yale team screens cardiac drugs that also attack cancer